2019 Annual Meeting Presentations

by Jennifer Pichardo || 7 days ago

Share Twitt Share Pin

PLEASE NOTE THAT SUBSEQUENT UTILIZATION OF MATERIAL PRESENTED DURING THE MEETING (SLIDES, TEXT, AND NARRATIVE) WITHOUT EXPRESS PERMISSION FROM THE AUTHOR IS NOT PERMITTED AND WILL BE CONSIDERED A COPYRIGHT VIOLATION. DELEGATES MUST REQUEST SPECIFIC PERMISSION FROM FACULTY MEMBERS IF THEY WISH TO REPRODUCE THEIR SLIDES FOR ANY PURPOSE.

Advocacy

1. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
2. Access to Care
   • Practice Management ¦ Edward J. Fox, MD, PhD
   • Quality Measures and Outcomes ¦ Sarah Benish, MD
   • Debate: Community-based Centers vs. Hospital-based Centers ¦ Edward J. Fox, MD, PhD; John Corboy, MD
   • Q&A ¦ Panel

Comprehensive Care

1. Essential Topics in Caring for Persons with Progressive MS 
   • Managing Difficult Conversations ¦ Marijean Buhse, PhD, MP-C, MSCN
   • Applying Primary Palliative Care to Those with Advanced MS ¦ Rachael Stacom, MS, ANP-BC, MSCN
   • Empowering Persons with MS: Planning for Future Needs ¦ Patti Nelson Reade, RN, Esq. CELA
   • Panel Discussion 
2. Caring for Women Across the Reproductive Lifespan
   • Welcome and Overview ¦ Riley Bove, MD
   • Counseling Women about Contraception and the Menstrual Cycle ¦  Riley Bove, MD
   • Pregnancy and MS: Safely Navigating Childbearing, from Pre-pregnancy Planning to the Post-partum Period ¦  Maria Houtchens, MD, MMsci
   • Menopause: A Time of Changes and an Opportunity to Re-evaluate Comprehensive Wellness and Care ¦ Riley Bove, MD
   • Healthy Aging Beyond the Menopause: Tackling “Below the Belt” Function and Other Aspects of Wellness ¦ Tamara Kaplan, MD
3. An MS Health Professional’s Guide to Cannabis Allen C. Bowling, MD, PhD
   • History, Botany, Pharmacology
   • Efficacy and Safety
   • Drug Interactions and Special Considerations
   • The Critical Role of MS Health Professionals
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)
   • History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
   • The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
   • Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
   • Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD
5. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
6. Multidisciplinary Management of Chronic Pain in MS
   • Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
   • Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
   • Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
   • Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
   • Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
   • Q&A ¦ Panel
7. The Importance of Community Based Programs to Enhance Comprehensive MS Care
   • Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
   • Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
   • Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
   • A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
   • The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS
8. Palliative Care in MS
   • Introduction ¦ Sarah Morrow, MD, MS, FRCPC
   • Description of the Consensus Conference-November 2018 ¦ Lori Mayer, DNP, MSN, RN, MSCN
   • Models of Palliative Care ¦ Rachel Stacom, MS, ANP-BC, MSCN
   • Clinical Experience Using the Palliative Care Model ¦ Benzi Kluger, MD, MS, FAAN
   • Case Studies with Learner Participation ¦ Panel
9. Update on Pediatric MS and Related Disorders
   • Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
   • Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
   • Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
   • Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN
10. Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care
    • Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
    • Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
    • Constraint-Induced Movement Therapy ¦ Victor Mark, MD
    • Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD
11. Fundamentals of Multiple Sclerosis Care 2019 (Part 3)
    • Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
    • Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
    • Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
    • Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
    • Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN
12. Mental Health Care Delivery Models for Patients with MS
    • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
    • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
    • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
    • Q&A
    • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
    • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
    • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
    • Q&A ¦ Panel
13. Platform Presentations: Disease Assessment and Management
    • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
    • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
    • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
    • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
    • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
    • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
14. Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS
    • Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
    • Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
    • Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
    • Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
    • Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
    • Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD
15. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
    • Introduction ¦ Jodie K. Haselkorn, MD, MPH
    • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
    • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
    • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
    • Implementing Strategies into a Clinical Setting ¦ Panel
16. Sex and MS: How to Help Patients with MS Who Experience Sexual DysfunctionKimberly Castelo, MS, LMFT, CST

Disease Management

1. Psychopharmacology and MS: Review and Update for Clinicians
   
   • Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
   • Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
   • Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel
2. Presidential Lecture: Use and Abuse of the McDonald Criteria in MS DiagnosisFred D. Lublin, MD
3. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 1)
   • History of Multiple Sclerosis ¦ Randall T. Schapiro, MD, FAAN
   • The Natural History of MS (Epidemiology, Immunology, Pathophysiology, Phenotypes) ¦ Bruce Cohen, MD
   • Making the Diagnosis: Disease Mimics, Use of Paraclinical Tools ¦ Derrick Robertson, MD
   • Primary Progressive MS: Diagnosis, Clinical Course, and Long-term Management ¦ Patricia K. Coyle, MD
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
5. Update on Pediatric MS and Related Disorders
   • Overview: Changing Landscape in MS and Neuroinflammatory Disorders in Youth ¦ Giulia Longoni, MD
   • Do Lifestyle and Environment Make a Difference in Pediatric MS? ¦ Ann Yeh, MD
   • Therapies for Pediatric MS ¦ Jennifer Graves, MD, PhD, MAS
   • Transitional Issues in Youth with MS ¦ Jennifer Boyd, RN, MHSc, MSCN
6. Practical Considerations in Relapse Management and Disease Modifying Therapy (DMT) Decision MakingBryan Walker, MHS, PA-C, MSCS; Stephanie Agrella, PhDc, MSN, RN, ANP-BC, MSCN
7. Basic Immunology for the Non-immunologist
   • How Does the Immune System Protect Us? ¦ Lisa Fox, PA
   • What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
   • How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
8. Advanced Immunology for the Non-immunologist
   • The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
   • The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
   • Q&A
9. Platform Presentations: Disease Modifying Therapy
   • DXM01: Efficacy and Safety of Alemtuzumab in Patients of African Descent in CARE-MS I and II: 8-Year Follow-up (TOPAZ Study) ¦ Annette Okai, MD
   • DXM02: Treatment Patterns of Disease-Modifying Therapy Among Pediatric Patients with Multiple Sclerosis in the United States ¦ Chinmay Deshpande, PhD
   • DXM03: Changes in the Immune Cell Profile, Clinical and Safety Outcomes in Fingolimod-Treated Patients with Relapsing Multiple Sclerosis: Interim Results of the FLUENT Study ¦ Yang Mao-Draayer, MD, PhD
   • DXM04: Real-World Efficacy of Delayed-Release Dimethyl Fumarate in Black or African American Patients with Multiple Sclerosis: 24-Month Interim Results from ESTEEM ¦ Mitzi Joi Williams, MD
   • DXM05: The Effects of Cladribine Tablets on Reduction in MRI Lesions Are Consistent across Subgroups in the ORACLE-MS ¦ Study Thomas Leist, MD
   • DXM06: Efficacy and Safety of the Bruton’s Tyrosine Kinase Inhibitor Evobrutinib (M2951) in Patients with Relapsing MS over 48 Weeks: A Phase II Study ¦ Jerry Wolinsky, MD (This speaker has opted not to publish this presentation.)
10. Platform Presentations: Disease Assessment and Management
    • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
    • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
    • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
    • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
    • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
    • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
11. Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management
    • Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
    • Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

Neuroscience / Environmental Factors

1. John F. Kurtzke Memorial Lecture: A Novel Subtype of Multiple SclerosisBruce D. Trapp, PhD
2. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology ss Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
3. Mechanisms of Disease Pathogenesis in MS
   • Control of Immunopathology in CNS Autoimmunity ¦ Thomas Korn, MD, PhD
   • Regulation of Autoimmune CNS Disease by IL-17 ¦ Rachel R. Caspi, PhD
   • Environmental Regulation of Astrocyte Pathogenic Activities ¦ Francisco J. Quintana, PhD
   • MS: An Immune Miscommunication Disease? ¦ Burkhard Becher, PhD
   • Distinct Roles for CD8 T Lymphocytes in Central Nervous System Autoimmunity ¦ Joan Goverman, PhD
   • How Do B Cell Directed Therapies Impact MS? ¦ Jennifer Gommerman, PhD
   • How IL-1 Regulates CNS Inflammation ¦ Ari Waisman, PhD
4. Presidential Lecture: Use and Abuse of the McDonald Criteria in MS DiagnosisFred D. Lublin, MD
5. Understanding the Mechanism of Action of B-cell Depleting Drugs: What Does that Reveal about the Role of B-cells in MS?
   • Introduction ¦ Gregory Wu, PhD
   • The Role of B Cell Antigen Presentation in EAE and MS ¦ Gregory Wu, PhD
   • B cell Responses of Adult and Pediatric Transverse Myelitis ¦ Nancy Monson, PhD
   • Disease Modifying Therapies Reveal Inflammatory and Anti-inflammatory Functions of B-cells in MS ¦ Robert Axtell, PhD
   • Mechanisms of Action of Ocrelizumab in MS ¦ Anne Cross, MD
   • Wrap-up ¦ Anne Cross, MD
6. Neuromyelitis Optica Spectrum Disorders: Current Issues in Diagnosis and Management
   
   • Overview ¦ Brian Weinshenker, MD
   • Diagnosis
     • Limited Syndromes: Myelitis, Optic Neuritis, Single and Recurrent ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
     • Brain Syndromes in NMOSD ¦ Marcelo Matiello, MD
     • Overlap of MS and NMO ¦ Anu Jacob, MD
     • NMO “Mimics” ¦ Anu Jacob, MD
     • Comorbidities: Autoimmunity (non-CNS, CNS) ¦ Brian Weinshenker, MD
     • Paraneoplastic NMOSD ¦ Marcelo Matiello, MD
   • Serologic Diagnosis
     • False Positive ¦ Marcelo Matiello, MD
     • False Negative (including MOG) ¦ Anu Jacob, MD
   • Management
     • Relapse Management: Consensus and Controversies ¦ Marcelo Matiello, MD
     • Indication for and Initial Treatment Choices for Long Term Therapy: Consensus and Controversies ¦ Anu Jacob, MD
     • Aggressive Disease/Treatment Failure ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
     • Pregnancy ¦ Brian Weinshenker, MD
     • Onset in Pregnancy/Relapse in Pregnancy
     • Maintenance Treatment: Planned and “Unplanned” Pregnancy
     • Stopping Therapy ¦ Dean Wingerchuk, MD, MSc, FRCP(C)
   • Conclusion Brian Weinshenker, MD
7. The Future of MS Imaging
   • Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
   • Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
   • Stretch ¦ Daniel Reich, MD, PhD
   • Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
   • Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
   • Discussion and Wrap-up
8. John Whitaker Memorial Lecture: Therapeutic Exploitation of Crosstalk Between the Immune and Nervous SystemsFrauke Zipp, MD
9. Whitaker Track Invited Lectures
   • Welcome and Introduction ¦ Michael K. Racke, MD
   • The Role of Stress Granules and RNA Binding Protein Dysfunction in the Pathogenesis of Neurodegeneration in MS ¦ Michael Levin, MD, FRCPC, FAAN, FANA
   • Serum Neurofilament Light Chain: The Neurologist‘s C-reactive Protein? Can We Rely on Serum NfL in the Future? ¦ Jens Kuhle, MD, PhD
   • Disability-specific and Sex-specific Approach to Neuroprotection in MS ¦ Rhonda Voskuhl, MD
   • Q&A, Closing ¦ Michael K. Racke, MD
10. Genetic Risk
    • Introduction and Objectives ¦ Sergio E. Baranzini, PhD
    • Genetic Susceptibility in MS ¦ Stephen Sawcer, MD, PhD
    • From Genes to Pathways: How Common Variants in DNA Can Result in MS Risk ¦ Sergio E. Baranzini, PhD
    • The Role of Rare DNA Variants in MS Susceptibility ¦ Chris Cotsapas, PhD
    • MS Genetics in Non-Europeans ¦ Jacob McCauley, PhD
11. Basic Immunology for the Non-immunologist
    • How Does the Immune System Protect Us? ¦ Lisa Fox, PA
    • What Causes CNS Inflammation in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
    • How Do the Current DMTs Affect the Altered Immune Response in MS? ¦ Scott D. Newsome, DO, MSCN, FAAN
12. Advanced Immunology for the Non-immunologist
    • The Innate Immune System: An Emerging Target in MS ¦ Michael Kornberg, MD, PhD
    • The Innate Immune System: Effect of MS Disease Modifying Therapies ¦ Robert J. Fox, MD
    • Q&A

Nursing

1. Challenges and Considerations with Infusible TherapiesAll Presentations
   • Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
   • Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
   • Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
   • Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
2. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
   • Introduction ¦ Jodie K. Haselkorn, MD, MPH
   • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
   • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
   • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
   • Implementing Strategies into a Clinical Setting ¦ Panel
3. Update on Communication Skills: Using New Tools in Conversations with Patients
   • Course Overview ¦ Marie Namey, APRN, MSCN
   • Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
   • Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
   • Panel Discussion ¦ Panel

Psychosocial: Cognition, Depression

1. Managing Fatigue and Sleep Disorders in People with MSAll Presentations
   • Invisible Symptoms: Prevalence Statistics of Fatigue and Sleep Disorders in MS ¦ Amy Sullivan, PsyD, ABPP
   • Modifying Empirically Validated Sleep Interventions for the MS Population ¦  Michelle Drerup, PsyD, DBSM
   • Research and Outcome Data on Treatment of Insomnia in the MS Population ¦  Catherine Siengsukon, PT, PhD
   • Ask the Experts ¦ Panel
2. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
3. Psychopharmacology and MS: Review and Update for Clinicians
   
   • Psychopharmacology Overview: Classification, Indications, Mechanism of Action, and Common Adverse Effects of Psychopharmacological Agents ¦ Jane Erb, MD
   • Use of Psychotropics in MS: Antidepressants, Antianxiety Agents, Mood Stabilizers, Antipsychotics, Cognitive Enhancers, and Cannabis  ¦ Laura Safar, MD
   • Psychotropics Algorithm Selection Based on Clinical Scenario – Clinical Vignettes Discussion with Audience Participation  ¦ Panel
4. Utilizing the Power of the Arts in MS Care: Everyone BenefitsAll Presentations
   • Introduction ¦ Francois Bethoux, MD
   • Medical Humanities through Arts in MS – Reflective Writing and Visual Arts  ¦ Ahmed Obeidat, MD, PhD
   • Use of Therapeutic Arts in an MS Clinic  ¦ Lisa Gallagher, MA, MT-BC
   • Evidence Supporting the Use of the Arts in the Management of MS  ¦ Francois Bethoux, MD
   • Musical Experience  ¦ Lisa Gallagher, MA, MT-BC
5. Affective Disorders and Personality Changes in MS
   • Introduction ¦ Frederick W. Foley, PhD
   • Epidemiology of Affective Disorders in MS: What We Know and What Gaps there are in Knowledge ¦ Scott B. Patten, MD
   • MRI Correlates and Pharmacological Treatment of Affective Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Personality Traits in Relation to Cognitive Impairment and Brain MRI in MS ¦ Ralph H B Benedict, PhD, ABPP-CN
6. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
7. Supporting and Caring For Each Other While Living with MS: The Support Partners’ PerspectiveAll Presentations
   • Introductions and Orientation to Session ¦ Deborah Miller, PhD, LISW
   • Presentation and Discussion of Vignette 1: Teen with MS and Mother ¦ Rosalind Kalb, PhD
   • Presentation and Discussion of Vignette 2: Newly Diagnosed Couple ¦ Matthew Sacco, PhD
   • Presentation and Discussion of Vignette 3: Older Couple ¦ Lucille Carriere, PhD
8. Mental Health Care Delivery Models for Patients with MS
   • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
   • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
   • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
   • Q&A
   • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
   • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
   • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
   • Q&A ¦ Panel
9. Managing the Suicidal Patient in Your Clinic: Red Flags, Ethical Considerations & Emotional AftermathAll Presentations
   • What We Know about Depression and Suicide in MS and their Impact on Individuals and their Families ¦ Rosalind Kalb, PhD
   • Before & After: Recognizing Red Flags, Dealing with the Aftermath ¦ Mary Alissa Willis, MD
   • Managing the Suicidal Patient in a Private Practice Setting: Legal and Ethical Considerations ¦ Amanda Rohrig, PT; Lauren R. Sankary, JD, MA
   • Interdisciplinary Discussion of Suicide-related Challenges ¦ Panel
10. Platform Presentations: Psychosocial: Cognition, Depression
    • PSY01: Cognition Following Mesenchymal Stem Cell Therapy in Multiple Sclerosis: An Interim Analysis ¦ Lisa Walker, PhD
    • PSY02: Contributions of the Rey Auditory Verbal Learning Test to Cognitive Impairment on the Brief International Cognitive Assessment for Multiple Sclerosis ¦ Abbey Hughes, PhD
    • PSY03: Neurobehavioral Correlates of Hazardous Cannabis Use in Multiple Sclerosis ¦ Abbey Hughes, PhD
    • PSY04: Using Connectome-Based Predictive Modeling to Derive Neuromarkers of Cognition in MS ¦ Ruchika Prakash, PhD
    • PSY05: Correlates of Cognitive Performance and Perceived Cognitive Abilities Among Hispanic and Black Individuals with Multiple Sclerosis ¦ Alexa Stuifbergen, RN, PhD, FAAN
    • PSY06: How Anxiety and Fatigue Interact to Interfere with Processing Speed in MS ¦ Caroline Altaras, MA
11. Case Studies in Cognition in MSJeffrey Wilken, PhD; Lori Ann Kostich, MS, CCC-SLP
12. Treatment Adherence in MS: Identifying Suboptimal Adherence and Strategies for Improving Appointment Attendance and Medication Self-Management
    • Introduction ¦ Jodie K. Haselkorn, MD, MPH
    • Using Clinical Data to Build Predictive and Explanatory Models of Treatment Adherence ¦ Elizabeth S. Gromisch, PhD
    • Psychological Considerations in Suboptimal DMT Adherence ¦ Aaron Turner, PhD, ABPP
    • Using Motivational Interviewing and Telehealth to Improve Adherence ¦ Aaron Turner, PhD, ABPP; Alicia Sloan, MPH, MSW
    • Implementing Strategies into a Clinical Setting ¦ Panel
13. Sex and MS: How to Help Patients with MS Who Experience Sexual DysfunctionKimberly Castelo, MS, LMFT, CST

Rehabilitation

1. Current Topics and Trends in MS Rehabilitation (Part 1)
   • Neuromodulation in MS ¦ Hesham Abboud, MD, PhD
   • Neuromuscular and Cardiovascular Considerations for Exercise in MS ¦ Alexander Ng, PhD, FACSM
2. Current Topics and Trends in MS Rehabilitation (Part 2)
   • MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦ Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS
3. Current Topics and Trends in MS Rehabilitation (Part 3)
   • Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
   • Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC
4. Platform Presentations: Rehabilitation
   • RHI01: Environmental Correlates of Physical Activity in Persons with Multiple Sclerosis ¦ Stephanie Silveira, PhD
   • RHI02: Physical Activity and Walking Performance across the Lifespan in Multiple Sclerosis ¦ Jessica Baird, PhD
   • RHI03: Physical and Cognitive Fatigue across the Lifespan in Persons with Multiple Sclerosis ¦ Catherine Jones, MSPH
   • RHI04: Psychometric Comparisons of Computer-Adaptive Test and Standard Balance and Walking Scales to Assess Functional Mobility in People with MS ¦ Hina Garg, PT, MS, PhD, NCS
   • RHI05: Persons with Multiple Sclerosis with Severe Disability Exhibit Muscular Strength Asymmetries in Both Upper and Lower Extremities ¦ John Farrell III, PhD
   • RHI06: Manual Dexterity and Computerized Cognitive Testing in People with Multiple Sclerosis: Motor Domain Reflects More Than Just What Is in the Hand ¦ Jared Srinivasan, BA
5. New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)All Presentations
   • Introduction ¦ Jodie Haselkorn, MD, MPH
   • Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
   • Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
   • Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
   • Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
   • Discussion ¦ Panel

Research

1. Opening Lecture: Mountains to Climb: The Cause, Treatment and Care of MS in the Pacific NorthwestJames Bowen, MD
2. Clinical Trials and Technology: What We Know, What is Coming?
   • Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
   • Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
   • Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
   • Q&A ¦ Andrew Goodman, MD, FAAN, FANA
3. The Evolving Research Landscape: Understanding, Designing, and Analyzing Studies in Multiple SclerosisAll Presentations
   • Introduction to Clinical Research: When, Why, and How ¦  Kavita Nair, PhD
   • Understanding and Interpreting Clinical Trial Design in Multiple Sclerosis ¦  Enrique Alvarez, MD, PhD
   • Real World Observational Studies in Multiple Sclerosis ¦  Carrie Hersh, DO, MSc
   • Q&A ¦  Panel
4. Current Topics and Trends in MS Rehabilitation (Part 2)
   • MS Rehab Research: Turning a Burning Clinical Question into a Research Project  ¦  Donna Fry, PT, PhD; Herb Karpatkin, PT, DSc, NCS, MSCS; Lori Ann Kostich, MS, CCC-SLP, MSCS

Skills Development

1. Interventions for Success at Work: Research to Application
   • Research Pertaining to Employment and MS ¦ Ralph H B Benedict, PhD, ABPP-CN
   • Medical Management Supporting the Employed Individual ¦ Amy Neal, MS PA-C
   • Supports Provided by Rehabilitation ¦ Lori Ann Kostich, MS, CCC-SLP, MSCS
   • Accommodations to Help Manage the Work Environment ¦ Shaheen Virani, MA, CRC
2. Challenges and Considerations with Infusible TherapiesAll Presentations
   • Introduction ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
   • Pre-infusion Preparation ¦ Colleen Harris, MN, NP, MSCN, MSCS
   • Infusions and Maintenance of Therapies ¦ Denise Bruen, MSN, APRN-BC, MSCN
   • Case Studies ¦ Colleen Harris, MN, NP, MSCN, MSCS; Denise Bruen, MSN, APRN-BC, MSCN
3. Update on Communication Skills: Using New Tools in Conversations with Patients
   • Course Overview ¦ Marie Namey, APRN, MSCN
   • Communication: The CPR of Healthcare ¦ E. Mary Johnson, RN, BSN, NE-BC
   • Shared Decision Making: Patient Centered Health Care ¦ Marie Namey, APRN, MSCN; Ellen Reardon, RN, MSN
   • Panel Discussion ¦ Panel

Symptomatic Management

1. Fibromyalgia and Myofascial Pain in MS PatientsDavid Brandes, MS, MD, FAAN, MSC
2. An MS Health Professional’s Guide to Cannabis Allen C. Bowling, MD, PhD
   • History, Botany, Pharmacology
   • Efficacy and Safety
   • Drug Interactions and Special Considerations
   • The Critical Role of MS Health Professionals
3. Multidisciplinary Management of Chronic Pain in MS
   • Introduction to Multidisciplinary Management of Chronic Pain in MS ¦ Kevin Alschuler, PhD
   • Management of the MS Patient with Chronic Pain ¦ Brett R. Stacey, MD
   • Is There a Role for Opioids in MS Pain Management? A Case-Based Discussion ¦ Pamela Stitzlein Davies, MS, ARNP, FAANP
   • Physical Activity and Chronic Pain in MS ¦ Robert W. Motl, PhD
   • Cognitive Behavioral Interventions for Chronic Pain ¦ Dawn M. Ehde, PhD
   • Q&A ¦ Panel
4. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
5. Fundamentals of Multiple Sclerosis Care 2019 (Part 3)
   • Multidisciplinary Approach to Symptom Management ¦ Beverly Layton, RN, BSN, CCRC, MSCN
   • Pearls from Advanced Practice: Disease Modifying Therapies ¦ Marie Moore, MSN, FNP, MSCN
   • Emerging Role of Pharmacists in MS Centers ¦ Brittany Denson, PharmD
   • Current Options in Comprehensive Fatigue Management ¦ Patricia Pagnotta, ANP-C, MSCN
   • Symptoms Below the Belt: Strategies in the Management of Elimination and Sexual Dysfunction ¦ Marie Namey, APRN, MSN, MSCN
6. Complex Symptoms in MS: Assessment and Management Strategies
   • Welcome and Overview ¦ Kathleen Costello, MS, ANP-BC, MSCN
   • Balance Issues in MS ¦ Jeffrey Hebert, PhD, PT
   • Spasticity and MS ¦ Susan Bennett, PT, DPT, EdD, NCS, MSCS
   • Visual Disturbances ¦ Robert K. Shin, MD
   • Q&A ¦ Panel
7. Mental Health Care Delivery Models for Patients with MS
   • The Current Landscape: Individuals with MS Need Better Access to Mental Health Services ¦ Sarah Minden, MD
   • Collaborative Care Model in Mental Health: Description, Components, and Review of its Evidence ¦ Jane Erb, MD
   • The Neurologist Perspective – Mental Health Needs of MS Patients and Role of the Neurologist ¦ Maria K. Houtchens, MD, MMsci
   • Q&A
   • Can the Collaborative Care Model Address the Mental Health Needs of Individuals with MS? Challenges and Opportunities ¦ Laura T. Safar, MD
   • The Social Worker Perspective – Care Management for MS Patients: Current Models and Future Developments ¦ Elizabeth Misasi, LICSW
   • Panel Discussion – Professional Adaptation and Role Changes in New Models ¦ Panel
   • Q&A ¦ Panel
8. Platform Presentations: Disease Assessment and Management
   • DXA01 Inroads: A Phase 3 Study to Assess the Efficacy and Safety of ADS-5102 (Amantadine) Extended Release Capsules in Multiple Sclerosis (MS) Patients with Walking Impairment ¦ Michelle Cameron, MD, PT, MCR
   • DXA02 Sleep Quality and Physical Activity in Youth with Multiple Sclerosis ¦ Stephanie Grover, MSc, CCRP
   • DXA03 Relevance of Timing of Mog Serum Testing: Does Positivity Always Signal Recurrence? ¦ Giulia Longoni, MD
   • DXA04 Impact of Cognitive Behavioral Therapy for Insomnia or Brief Sleep Education on Insomnia Symptoms, Fatigue, Depression, and Anxiety in Individuals with Multiple Sclerosis ¦ Stacy Coffyn, SPT
   • DXA05 Physical Activity, Sedentary Behavior, and Sleep Quality in Adults with Multiple Sclerosis across the Lifespan ¦ Katie Cederberg, MS
   • DXA06 The Economic Impact of Multiple Sclerosis: A Preliminary Look at the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS) (on behalf of the NARCRMS HEOR Advisory Group) ¦ Kottil Rammohan, MD
9. Beyond the PI: Drug-Drug Interactions (DDIs), Monitoring and Management
   • Precision Medicine and Applied Pharmacology for Anti-Depressants, Anti-Psychotics to Assist in Drug Selection and Monitoring to Avert Comorbidities in Patients with MS ¦ Rebecca Barnhart, PharmD, BCPP
   • Anatomy of Pharmacokinetic/ Pharmacodynamic Drug Interaction Implications ¦ Felecia Hart, PharmD, MSCS

Technological Advances

1. Whitaker Platform Presentations
   
   • Welcome and Introduction ¦ Michael Racke, MD
   • A Model for Examining Novel Mechanisms of Neurodegeneration in an Animal Model of Multiple Sclerosis ¦ Cole Libner, BSc
   • Does 4 Weeks of Cognitive Rehabilitation Improve Processing Speed and Working Memory in MS? Results of Mindfulness Training Vs. Adaptive Computerized Training ¦ Heena Manglani, MA
   • Dysfunctional RNA Binding Protein Biology as Contributors to the Pathogenesis of Autoimmune Disease of the Central Nervous System ¦ Hannah Salapa, BS
   • Interferon Signature and Regulation in Progressive Multiple Sclerosis: Effects of Sc IFN-Beta-1a ¦ Xuan Feng, PhD
   • Q&A, Closing ¦ Michael Racke, MD
2. Clinical Trials and Technology: What We Know, What is Coming?
   • Responsibilities of the Investigator: Current Use of Electronic Data Capture ¦ Andrew Goodman, MD, FAAN, FANA
   • Research Technology in the Clinic: A Learning Health Care System ¦ Kelsey Yoo, PA
   • Telemedicine Techniques in Clinical Research: Current and Future Use ¦ Lee Gerwitz, MD
   • Q&A ¦ Andrew Goodman, MD, FAAN, FANA
3. The Future of MS Imaging
   • Welcome and Goals: Presenting the NAIMS Cooperative ¦ Daniel S. Reich, MD, PhD
   • Role of Advancing Imaging in Diagnosing (and Not Misdiagnosing) MS ¦ Andrew Solomon, MD
   • Stretch ¦ Daniel Reich, MD, PhD
   • Role of Advanced Imaging in Predicting and Tracking MS Course ¦ Jiwon Oh, MD, PhD, FRCPC
   • Role of Advanced Imaging in Unraveling MS Pathophysiology ¦ Pascal Sati, PhD
   • Discussion and Wrap-up
4. Current Topics and Trends in MS Rehabilitation (Part 3)
   • Occupational Therapy Assessment and Intervention in Multiple Sclerosis: A Behavior-based Approach ¦ Shaina Meyer, OTR/L, MSCS; Rebecca Cunningham, OTD, OTR/L
   • Computer Based Rehab Outcome Measures: The Future is Now ¦ Matt Sutliff, PT, DPT, MSC
5. New Technology in MS
   • The Brave New World of Technology ¦ Gabriel Pardo, MD, FAAN
   • Digital Innovations; Reshaping How We See MS ¦ Daniel Pelletier, MD
   • New Approaches to Solving Old Problems ¦ Darin Okuda, MD
   • Q&A ¦ Panel
6. New Developments in MS Rehabilitation and Telerehabilitation (VA MSCoE)All Presentations
   • Introduction ¦ Jodie Haselkorn, MD, MPH
   • Overview of Existing Telerehabilitation in MS in Current Practice ¦ Mitchell T. Wallin, MD, MPH
   • Novel Applications of Telerehabilitation Technology ¦ Shane Chanpimol, PT, DPT
   • Strategies to Enhance Function in MS through Rehabilitation Intensity, Duration and Timing ¦ Jodie Haselkorn, MD, MPH
   • Current Evidence-based Rehabilitation Interventions for Fall Prevention in MS ¦ Michele Cameron, MD, PT, MCR
   • Discussion ¦ Panel

Wellness

1. Improving the Health and Wellness of People with Advanced MS through Community Partnerships
   • Creating Partnerships for Healthier Outcomes ¦ Rachael Stacom, MS, ANP-BC, MSCN
   • Building an Effective Peer Support/Mentoring Program for People Living with Multiple Sclerosis ¦ Elaine Castelluccio, PT, MPT, MSCS
   • Being a Peer Mentor: The Lived Experience ¦ Cathy Kiler-McFadden
2. The Importance of Community Based Programs to Enhance Comprehensive MS Care
   • Welcome and Introduction of Speakers ¦ Brian Hutchinson, PT, MSCS
   • Community-Based Wellness Models for Chronic Disease ¦ Brian Hutchinson, PT, MSCS
   • Building MS Communities, Expanding the Continuum of Care ¦ James Bowen, MD
   • A Community Based Yoga Program for People with MS: The Power of Connection ¦ Megan Weigel, DNP, ARNP-c, MSCN
   • The Multiple Sclerosis Achievement Center: A Day Program Model for People with MS ¦ Brian Hutchinson, PT, MSCS
3. Fundamentals of Multiple Sclerosis Care 2019: Identifying the Disease and Managing the Course (Part 2)
   • RRMS: Current Treatment Options, Considerations in Choosing Treatment, Acute Relapse Management ¦ John Rinker, MD
   • Identifying and Managing Mood Disorders in MS ¦ Anthony Feinstein, MD, PhD
   • Women’s Issues in MS: Pregnancy, Menopause, Sexual Function ¦ Mitzi Joi Williams, MD
   • Integrative Medicine in the Comprehensive Care Model of MS ¦ Megan Weigel, DNP, ARNP-C, MSCN
4. Integrative Medicine: An Essential But Neglected Component of Comprehensive MS Care
   • Introduction, Relevance to Comprehensive Care, Science and Clinical Application, Research Update ¦ Allen C. Bowling, MD, PhD
   • Calorie-Restriction and Other Dietary Modification Strategies for MS Course ¦ Kathryn Fitzgerald, ScD, ScM
   • Constraint-Induced Movement Therapy ¦ Victor Mark, MD
   • Can High Intensity Training in MS Further Optimize Exercise Therapy Outcome? ¦ Charly Keytsman, PhD
5. Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS
   • Leveraging Multidisciplinary Care to Enhance Wellness in Individuals with MS ¦ Gloria von Geldern, MD
   • Encouraging Wellness Behaviors and Integrating Wellness into Neurologic Care ¦ Annette Wundes, MD
   • Guiding Patients through the Complex World of MS Care ¦ Debra Cramer, RN
   • Physiatry and Rehabilitation Therapy Interventions to Promote Wellness ¦ Gloria Hou, MD
   • Promoting Wellness through Education, Employment, and Volunteering ¦ Joe Stuckey, MS, CRC
   • Promoting Wellness Behaviors through Health Behavior Change Interventions ¦ Samantha Artherholt, PhD

Share Twitt Share Pin